Formoterol in acute asthma in children 6-14 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Economic evaluation of eformoterol compared with salmeterol in children aged 6-17 years with symptomatic asthma in the UK: cost-effectiveness results of the FACT study Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001
Characterization of severe asthma in children over 6 years Source: International Congress 2017 – Diagnostic tools in paediatric asthma Year: 2017
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017
Randomized trial of HFA-salbutamol versus CFC-salbutamol via MDI with spacer for acute wheezing exacerbations in children less than 2 years of age Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002
Efficacy of fluticasone propionate in infants younger than two years with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
A comparison of nebulized budesonide, intramuscular and oral dexamethasone in the treatment of croup among children aged 6-36 months Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003
Outcomes over the first two years of treatment with mepolizumab in severe asthma Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021 Year: 2021
Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Safety of Inhaled fluticasone propionate in children 2-4 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3 Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002